Streetbeat News

Analyst Ratings

RETA

Baird analyst Brian Skorney maintains an Outperform rating on Reata Pharmaceuticals (NASDAQ:RETA) and raises the price target from $85 to $173.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 7:58 pm

GNTX

Baird analyst David Leiker has maintained an Outperform rating on Gentex (NASDAQ:GNTX) and raised the price target from $35 to $37.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 7:56 pm

DT

Baird analyst William Power maintains an Outperform rating on Dynatrace (NYSE:DT) and raises the price target from $53 to $59.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 7:55 pm

AVTR

Avantor Inc (NYSE:AVTR) reported Q2 adjusted EPS of $0.28, missing the consensus of $0.29. Sales decreased 8.7% to $1.74 billion, below the consensus of $1.80 billion. The company's stock sold off 7% on Friday and trades at just 14.1 times EBITDA. William Blair analyst Matt Larew has downgraded Avantor to Market Perform from Outperform due to a challenging competitive environment. The company expects core organic revenue to decline 6.5%-4.5% in 2023.

Portfolio Pulse from Vandana Singh

July 31, 2023 | 7:53 pm

OLN

Stifel analyst Vincent Anderson has maintained a 'Buy' rating on Olin (NYSE:OLN) but lowered the price target from $85 to $82.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 7:52 pm

CHTR

B of A Securities analyst Jessica Ehrlich maintains a Neutral rating on Charter Communications (NASDAQ:CHTR) and raises the price target from $425 to $450.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 7:50 pm

NET

RBC Capital analyst Matthew Hedberg has maintained an Outperform rating on Cloudflare, Inc (NYSE:NET) and raised the price target from $54 to $71. Despite near-term macroeconomic fluctuations, Hedberg sees long-term potential in the company. He expects a slight upside to estimates as the company continues to work through GTM changes. The price target boost reflects peer group multiple expansion as he continues to like the company's long-term opportunity.

Portfolio Pulse from Anusuya Lahiri

July 31, 2023 | 7:49 pm

CHCO

Piper Sandler analyst Casey Orr Whitman maintains a Neutral rating on City Holding (NASDAQ:CHCO) and raises the price target from $93 to $103.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 7:48 pm

BAH

TD Cowen analyst Cai Rumohr maintains an Outperform rating on Booz Allen Hamilton (NYSE:BAH) and raises the price target from $123 to $144.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 7:47 pm

CVS

A significant amount of unusual options activity has been observed for CVS Health (NYSE:CVS), indicating a bullish stance by a large investor or institution. The sentiment among these big-money traders is split between 54% bullish and 45% bearish. The targeted price range for CVS Health over the last 3 months has been from $60.0 to $77.5. Barclays, JP Morgan, and Mizuho have maintained their positive ratings on CVS Health, with price targets of $89, $106, and $88 respectively.

Portfolio Pulse from Benzinga Insights

July 31, 2023 | 7:47 pm